Pacira Pharmaceuticals, an acute care specialty pharmaceutical company, has appointed James Scibetta, as its new CFO.
Subscribe to our email newsletter
Mr Scibetta brings more than 20 years of financial leadership experience in private and public companies as well as investment banking to Pacira. Most recently he has been consulting to Genzyme following his instrumental role as CFO of Bioenvision in its 2007 sale to Genzyme for $345 million.
Prior to his tenure at Bioenvision Mr Scibetta was executive vice president and CFO of Merrimack Pharmaceuticals, where he aided the company in raising over $140 million of equity and debt capital. Mr Scibetta is a member of the board of directors and chairman of the audit committee of both Labopharm and Nephros.
Dave Stack, Pacira president and CEO, said: “Jim brings outstanding experience and financial leadership with a strategic perspective focused on value creation to Pacira. We expect his contributions to enhance our organizational management, growth, and capital markets strategic initiatives.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.